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In the last few years, the advent of new technological approaches has led to a better
knowledge of the ontogeny of erythropoiesis during development and of the journey
leading from hematopoietic stem cells (HSCs) to mature red blood cells (RBCs). Our
view of a well-defined hierarchical model of hematopoiesis with a near-homogeneous
HSC population residing at the apex has been progressively challenged in favor of a
landscape where HSCs themselves are highly heterogeneous and lineages separate
earlier than previously thought. The coordination of these events is orchestrated by
transcription factors (TFs) that work in a combinatorial manner to activate and/or repress
their target genes. The development of next generation sequencing (NGS) has facilitated
the identification of pathological mutations involving TFs underlying hematological
defects. The examples of GATA1 and KLF1 presented in this review suggest that in the
next few years the number of TF mutations associated with dyserythropoietic disorders
will further increase.
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INTRODUCTION
Erythropoiesis leads to the production of the proper number of RBCs required by the body under
homeostatic and stress conditions. In healthy adults, erythropoiesis ensures the release in the blood
stream of 2 × 106 RBCs/second, but this number dramatically increases to respond to inadequate
tissue oxygenation (Tsiftsoglou et al., 2009; Dzierzak and Philipsen, 2013; Nandakumar et al., 2016).
Insufficient quantitative or qualitative production of fully functional RBCs, whether acquired or
inherited, results in a wide spectrum of diseases generally defined as anemias.
The causes of anemias are variable and reflect the complexity of the differentiation
and maturation of erythrocytes. In some cases, the number of RBCs is extremely low
because of the failure to produce erythroid progenitors, as in Diamond-Blackfan Anemia
(DBA) (Da Costa et al., 2018). In other cases, impaired differentiation leads to the
accumulation of erythroid precursors in the bone marrow [β-thalassemia (Rivella, 2015),
congenital dyserythropoietic anemia, CDA (Iolascon et al., 2011)] or to the unbalanced
production of different blood cell types [myelodysplastic syndromes, MDS (Levine et al.,
2007; Lefevre et al., 2017)], resulting in insufficient RBC numbers in the bloodstream.
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In other forms of anemias, RBCs are produced but defects
in some crucial gene products [typically specific enzymes
(Koralkova et al., 2014; Grace et al., 2018), membrane proteins
or cytoskeletal components (Mohandas and Gallagher, 2008;
Perrotta et al., 2008), sickle globin chains (Rees et al., 2010),
channel proteins (Glogowska and Gallagher, 2015), specific
pathways (Bianchi et al., 2009; Schwarz et al., 2009)] result in
RBCs with decreased oxygen delivery capacity and/or shortened
lifespan. Very often, different diseases share common features:
for example imbalanced globin chains in β-thalassemia is
accompanied by the accumulation of defective precursors in the
bone marrow and by ineffective erythropoiesis (IE), as is also
observed in CDA (Libani et al., 2008; Iolascon et al., 2011; Ribeil
et al., 2013; Rivella, 2015).
Recently, thanks to the advent of new technologies, including
NGS using small pools of cells or single cells (Nestorowa et al.,
2016; Paul et al., 2016; Ye et al., 2017; Giladi et al., 2018), the
development of improved panels of surface markers (Guo et al.,
2013; Notta et al., 2016) and the design of in vivo cell tracing
systems (Dykstra and Bystrykh, 2014; Perie et al., 2014; Pei
et al., 2017; Rodriguez-Fraticelli et al., 2018; Upadhaya et al.,
2018), our understanding of hematopoiesis -and erythropoiesis-
has greatly expanded. In parallel, genome wide association
approaches (GWAS) (Menzel et al., 2007; Sankaran et al., 2008;
Uda et al., 2008; Soranzo et al., 2009; van der Harst et al., 2012),
massive genome and exome sequencing (Chami et al., 2016) led
to the identification of new variant/modifier alleles influencing
erythropoiesis associated with TFs.
In this scenario, TFs not only control lineage commitment
transitions but are emerging as key-players underpinning, so far
unexplained erythroid diseases. Here, we consider GATA1 and
KLF1 as paradigmatic TFs. By focusing on these examples, we aim
to provide evidence of their pleiotropic effects rather than to give
a complete list of GATA1 or KLF1 mutations identified so far.
ERYTHROPOIESIS
Erythropoiesis During Development
The first wave of erythropoiesis originates in the yolk sac,
where Primitive Erythroid Cells (EryPs) sustain the oxygenation
demand of the growing embryo (Dzierzak and Philipsen, 2013).
EryPs are large in size and still nucleated when released in the
circulation, where they later enucleate (Isern et al., 2011; Dzierzak
and Philipsen, 2013; Palis, 2014). In mouse, at E8.25 a second
wave of erythro-myelo-precursors (EMPs) originates in the yolk
sac and colonizes the fetal liver, generating the first definitive
RBCs (Palis, 2016). Finally, around E10.5, hematopoietic stem
cells (HSCs) from aorta-gonad-mesonephros (AGM), placenta
and possibly other yet unknown sites, colonize the fetal liver.
These cells will sustain definitive hematopoiesis for the remainder
of gestation and, around birth, will migrate to the bone marrow,
the site of adult hematopoiesis (Dzierzak and Philipsen, 2013).
From HSC to RBC
Until recently, the “classical model” of hematopoiesis was
considered a paradigm of a stepwise, hierarchical cellular
specification system, whereby HSCs generated multipotent
progenitors with progressively restricted lineage potential
through a sequence of binary choices. The grand entrance of new
single-cell separation technologies, in vivo lineage tracing systems
and single-cell analysis, provided novel and surprising insights,
prompting the idea that early transcriptional priming develops
into the acquisition of specific lineage programs (Cabezas-
Wallscheid et al., 2014; Haas et al., 2018). In this context,
erythroid cells would originate early in the hematopoietic
hierarchy, i.e., from stem/multipotential progenitor stages (Guo
et al., 2013; Notta et al., 2016; Tusi et al., 2018), soon after the
emergence of the megakaryocytic lineage (Upadhaya et al., 2018).
The first clearly recognizable unipotent erythroid progenitor,
identified decades ago in in vitro clonogenic assays, is the BFU-
E (burst-forming unit-erythroid), that differentiate into rapidly
dividing colony-forming-unit erythroid (CFU-E) (Hattangadi
et al., 2011; Koury, 2016; Dulmovits et al., 2017). The
entry of CFU-Es into erythroid terminal differentiation marks
the transition into final maturation (Hwang et al., 2017;
Tusi et al., 2018).
EXTRACELLULAR AND
INTRACELLULAR SIGNALS
Red blood cell differentiation, their production in homeostatic
and stress condition, is governed by an integrated complex
interplay of extracellular and cell-cell signals within the
microenvironment that activate the appropriate downstream
intracellular signals, ultimately converging on key TFs. Although
these aspects are beyond the scope of this review, we give
a glimpse of the major players in these regulatory networks
in Figure 1.
THE ROLE OF TRANSCRIPTION
FACTORS
Transcription factors, together with cofactors and chromatin
modifiers, dictate the lineage-specific, stage-specific
transcriptional programs by coordinately activating and/or
repressing their targets through their binding to DNA (Portela
and Esteller, 2010; Dore and Crispino, 2011; Love et al., 2014).
The advent of NGS has rapidly expanded our understanding
of TFs functions in physiological erythropoiesis, discovering
TF mutations as cause of yet unexplained hematological -and
dyserythropoietic- defects. Here, we focus on the key examples
of GATA1 and KLF1 and their mutations to provide a glimpse of
the complexity of their actions (Figure 2).
The Example of the “Master Regulator”
GATA1
The X-linked GATA1 gene encodes a zinc finger TF expressed
in the hematopoietic system in erythroid, megakaryocytic and,
at lower levels, in eosinophilic, dendritic, and mast cells (Yu
et al., 2002a; Ferreira et al., 2005; Gutierrez et al., 2007;
Kozma et al., 2010).
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FIGURE 1 | Erythropoiesis and megakaryopoiesis are regulated at multiple levels. A complex network of extracellular signals -activating intracellular signaling
pathways-, cell–cell interactions within the niche and intracellular effectors regulate cell differentiation in homeostatic conditions and in response to stress stimuli
(Ferreira et al., 2005; Hattangadi et al., 2011; Songdej and Rao, 2017). These signals converge on TFs and chromatin modifiers which ultimately define the
transcriptome at each given stage. The main growth factors, integrins and transcription factors involved in these processes are indicated. The GATA1 (red rectangles)
and KLF1 (green rectangles) windows of expression are indicated (see also Figure 2B). HSC, Hematopoietic Stem cell; TPO, thrombopoietin; SCF, Stem cell Factor;
IL, interleukin; SDF-1, stromal-derived factor-1; GPIIb/IIIa, integrins αIIb/β3 (CD41/CD61); EPO, erythropoietin; GCs, glucocorticoids. α4/β1, integrins α4/β1
(CD49d/CD29).
GATA1 has three main functional domains: an N-terminal
activation domain (N-TAD) and two homologous zinc (Zn)
finger domains in the C-terminal half of the protein. The
N-terminal Zn finger binds to the GATA1 main cofactor FOG1
(Friend-of-GATA) and modulates the affinity of GATA1 for
binding to complex sites in vitro (Trainor et al., 1996; Newton
et al., 2001; Yu et al., 2002b). The C-terminal Zn finger (C-ZnF)
binds to DNA (WGATAR motif).
GATA1 produces two isoforms: the full length protein
(GATA1-FL, 47 kDa) and a shorter variant (GATA1s, 40 kDa),
translated from codon 84 within the third exon. GATA1s lacks
the N-TAD and results in a protein with a reduced transactivation
activity (Calligaris et al., 1995). Gata1 knockout in mice (Pevny
et al., 1991) results in embryonic lethality around E10.5–E11.5
due to severe anemia, with GATA1-null cells undergoing massive
apoptosis at the proerythroblastic stage (Pevny et al., 1995;
Fujiwara et al., 1996). The conditional erythroid knockout in
adult mice causes aplastic anemia, revealing its essential role in
both steady-state and stress erythropoiesis (Gutierrez et al., 2008).
By contrast, megakaryoblasts lacking GATA1 proliferate
abnormally but fail to undergo terminal differentiation
(Shivdasani et al., 1997; Vyas et al., 1999). Since these first
studies, many other reports revealed the many roles of GATA1
in the erythro/megakaryocytic differentiation (Ferreira et al.,
2005). GATA1 mutations identified in patients underscore this
pleiotropy: mutations altering the quantity or quality of GATA1
can lead to a variety of phenotypes. Depending on the type
of mutation and whether germline or somatic, the severity
Frontiers in Physiology | www.frontiersin.org 3 February 2019 | Volume 10 | Article 91
fphys-10-00091 February 9, 2019 Time: 17:7 # 4
Barbarani et al. GATA1 and KLF1 in Dyserythropoiesis
FIGURE 2 | (A) Schematic structure of GATA1 and KLF1 proteins and of their DNA-binding motifs. The position of the mutations discussed in this review are
indicated. ZnF, zinc fingers; TAD, transactivation domains. The DNA consensus are from the JASPAR database (http://jaspar2016.genereg.net/). (B) Phenotype of
GATA1 (Pevny et al., 1991, 1995; Fujiwara et al., 1996; Shivdasani et al., 1997; Gutierrez et al., 2008) and KLF1 (Nuez et al., 1995; Perkins et al., 1995; Hodge et al.,
2006; Nilson et al., 2006; Frontelo et al., 2007; Tallack and Perkins, 2010) gene knockouts in mouse.
of the disease and the involvement of the erythroid and/or
megakaryocytic compartments greatly varies.
“QUANTITATIVE MUTATIONS”: GENE
DOSAGE AND BACKGROUND EFFECTS
AT WORK
Mutations Causing GATA1-FL Loss:
Inherited
Diamond-Blackfan anemia (DBA) is an inherited bone marrow
failure syndrome characterized by severe anemia due to a
great reduction in BFU-Es, without involvement of other
hematopoietic lineages. Heterozygous mutations in ribosomal
proteins account for about 65% of DBA cases. In 2012 an
exome sequencing approach discovered the first GATA1 mutation
in a DBA patient (Sankaran et al., 2012). This mutation
(c.220G > C transversion) causes the skipping of exon 2,
determining GATA1-FL loss, while retaining GATA1s. Unrelated
DBA patients were reported to carry the same mutation (Klar
et al., 2014), or mutations in the ATG of GATA1-FL (Ludwig
et al., 2014; Parrella et al., 2014). Of interest, in a family
reported by Hollanda et al. (2006) the inherited loss of GATA1-
FL results in macrocytic anemia of various severity in the
different patients (with variable involvement of megakaryocytes
and neutrophils).
Mutations Causing GATA1-FL Loss:
Acquired
Somatic mutations in GATA1, preventing the synthesis of
GATA1-FL, predispose newborn Down Syndrome (DS) patients
to develop (in 10–20% of cases) transient myeloproliferative
disease (TMD) (Wechsler et al., 2002; Xu et al., 2003;
Hitzler and Zipursky, 2005). This pre-leukemic condition often
spontaneously resolves. However, in about 30% of TMD cases,
it develops into acute pediatric megakaryoblastic leukemia
(AMKL) (Wechsler et al., 2002; Magalhaes et al., 2006). All
the DS-TMD GATA1 mutations identified so far, map in
exon 2 and either introduce a STOP codon or alter splicing
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such that only GATA1s is translated (Mundschau et al.,
2003; Rainis et al., 2003). The loss of GATA1-FL in pre-
malignant cells characterizes virtually all cases of DS-TMD.
The detection of clone-specific GATA1 mutations in DS-
TMD and AMKL proves that AMKL derive from the TMD
clone (Rainis et al., 2003; Ahmed et al., 2004; Hitzler and
Zipursky, 2005). Moreover, GATA1 mutations are extremely
rare in AMKL blasts of non-DS patients, clearly indicating
a specific cooperation of GATA1 mutations with trisomy 21
(Gruber and Downing, 2015). The restoration of GATA1-FL
expression in DS-AMKL-derived cells partially restores erythroid
differentiation, further supporting the notion that the loss of
GATA1-FL is essential for leukemogenesis (Xu et al., 2003).
Importantly, DS-AMKL GATA1 mutations have very little effect
on erythropoiesis, suggesting that the co-occurrence trisomy 21
confers the property of specific targeting megakaryoblasts in
DS patients.
Various evidences suggest that TMD likely emerges in a
yolk sac/fetal liver progenitor in utero (Shimada et al., 2004).
In agreement with this hypothesis, in mouse, a knockin allele
abolishing GATA1-FL (and leaving GATA1s intact) results
in a transient reduction of erythroid cells accompanied by
increased megakaryopoiesis that resolves around E14.5 (Li
et al., 2005). Despite these observations, the fetal cell type
originating TMD and molecular mechanisms by which GATA1
mutations specifically synergizes with trisomy 21 are still unclear
(Crispino, 2005).
GATA1 Low Levels and Disease
The notion that low levels of GATA1 lead to the development
of myelofibrosis comes from studies in the GATA1-low mouse
model, that also develops anemia with age (Vannucchi et al.,
2002). In line with this first observation, the majority of
patients with primary myelofibrosis (PMF) have GATA1-
deficient megakaryocytes (Migliaccio et al., 2005). Of interest,
in PMF patients, the reduced level of GATA1 is due to its
impaired translation secondary to RPS14 deficiency (Gilles et al.,
2017). The connection between GATA1 levels and RP proteins
hinges on additional observations: indeed, in cells from DBA
patients who are haploinsufficient for RPS19, GATA1 translation
is greatly reduced (Ludwig et al., 2014; O’Brien et al., 2017;
Khajuria et al., 2018).
Together, these examples again point toward the importance
of the correct GATA1 protein dosage and indicates GATA1





Mutations Abolishing the Interaction
With FOG1
In Tsang et al. (1997) identified by yeast two-hybrid a
novel zinc finger protein, named FOG1, binding to the
N-ZnF of GATA1. GATA1 mutants unable to bind FOG1
(but still retaining DNA binding) do not rescue the
severe block in terminal erythroid maturation of GATA1-
deficient cells (Tsang et al., 1997). Instead, a compensatory
FOG1 mutation restoring the interaction, rescues the
GATA1− phenotype, demonstrating that the interaction
between the two proteins is essential for erythroid and
megakaryocytic differentiation (Crispino et al., 1999; Chang
et al., 2002). In Nichols et al. (2000) described a family
with dyserythropoietic anemia and thrombocytopenia
caused by a GATA1 (V205M) mutation abolishing the
GATA1:FOG1 interaction.
Other Allelic Variants, Other Interactions,
Other Phenotypes
Remarkably, distinct substitutions at a single residue lead to
very different outcomes, underlying the complexity of the
GATA1 networks. The R216Q substitution causes X-linked
thrombocytopenia with β-Thalassemia (Yu et al., 2002b; Balduini
et al., 2004), whereas R216W patients also show features of
congenital erythropoietic porphyria (CEP) (Phillips et al., 2007;
Di Pierro et al., 2015). The D218Y mutation causes severe
thrombocytopenia with anemia (Freson et al., 2002), whereas
the D218G substitution causes macrothrombocytopenia with
mild dyserythropoiesis and no anemia (Freson et al., 2001;
Mehaffey et al., 2001).
Notably, whereas the D218Y diminishes the FOG1:GATA1
interaction, the D218G and R216Q do not, but they rather
impair GATA1 ability to recruit the TAL1 cofactor complex
(Campbell et al., 2013).
MUTATIONS IN THE GATA1 DNA TARGET
SEQUENCES AS A CAUSE OF HUMAN
ERYTHROID DISORDERS
Ultimately, TFs elicit their function by binding to DNA
motifs on their target genes. Thus, it is expected that
mutations creating new -or disrupting- specific binding sites
could have phenotypic consequences. Although these mutations
remain very elusive, over the years an increasing number
of cases has accumulated, implicating these polymorphisms
as a source of disease. Such mutations have been associated
with congenital erythropoietic porphyria (Solis et al., 2001),
X-linked sideroblastic anemia (Campagna et al., 2014; Kaneko
et al., 2014), pyruvate kinase deficiency (Manco et al., 2000),
CDAII (Russo et al., 2017), Bernard–Soulier syndrome (Ludlow
et al., 1996) or linked to erythroid trait variants such
as δ-thalassemia (Matsuda et al., 1992) and blood groups
(Tournamille et al., 1995; Nakajima et al., 2013; Oda et al.,
2015; Moller et al., 2018). Interestingly, a mutation abolishing
a GATA1 consensus in the KLF1 promoter (see below),
causes a reduction of KLF1, which in turn results in reduced
transcription of the KLF1 target genes more sensitive to KLF1
levels, such as BCAM, encoding for the Lutheran (Lu) antigen
(Singleton et al., 2008).
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E/KLF1: An Unsuspected Key-Player in
Various Types of Dyserythropoiesis
KLF1 gene, located on chromosome 19, encodes for a proline-
rich protein containing three zinc fingers (Bieker, 1996; Mas
et al., 2011; Figure 1B), expressed in the bone marrow and
in the erythroid lineage. KLF1 mainly acts by recruiting
coactivators and chromatin remodelers, thus contributing to
the large epigenetics changes which shape erythroid maturation
(Shyu et al., 2014).
As for GATA1, the first evidence for an essential role in
erythropoiesis came from the observation that KLF1 knockout
mice die in utero around E15 due to fatal anemia (Nuez
et al., 1995; Perkins et al., 1995). Given that KLF1 is an
important activator of β-globin, lethality was first attributed
to β-thalassemia. However, this is not the sole explanation for
the defect: the rescue of the α/β imbalance obtained by the
transgenic expression of γ-globin is not sufficient to rescue
hemolysis, thus pointing to additional roles for KLF1 (Perkins
et al., 2000). In 2015, the first case of severe neonatal anemia with
kernicterus due to KLF1 compound heterozygosis was described
in man (Magor et al., 2015), with an erythroid phenotype largely
mirroring that observed in mice: hydrops fetalis, hemolytic
anemia, jaundice, hepatosplenomegaly, marked erythroblastosis
and high levels of HbF. Another report confirms that in humans,
although compatible with life, the loss of KLF1 severely impairs
erythropoiesis (Lee et al., 2016).
QUANTITATIVE MUTATIONS OF KLF1:
HAPLOINSUFFICIENCY/HYPOMORPHIC
ALLELES
KLF1 is haplosufficient. The loss of one allele is asymptomatic
and only genes particularly sensitive to KLF1 gene dosage
are affected. This is observed in the Lutheran In(Lu) Blood
group, where either frameshift mutations, introducing
premature termination, or amino acids substitutions in
the zinc binding domain, lead to reduced or ineffective
KLF1 production (Singleton et al., 2008; Helias et al., 2013).
Interestingly, the search for possible mutations in an erythroid
TF -that turned out to be KLF1- as a cause of the In(Lu)
phenotype came from transcriptomic analyses showing
that In(Lu) cells express reduced levels of many erythroid-
specific genes associated with red cell maturation, including
BCAM (encoding for the Lu antigen), ALAS2, HBB, SLC4A1,
and CD44 (Singleton et al., 2008). More recently, extended
serological and FACS analysis of In(Lu) samples also revealed
a reduced expression of CD35, ICAM4, and CD147 (Fraser
et al., 2018). Interestingly, in one single case the In(Lu)
phenotype has been associated with a GATA1 mutation (X414R)
(Singleton et al., 2013).
It is now clear that different KLF1 target genes are
differentially sensitive not only to KLF1 levels (when one allele
carries an inactivating mutation), but also to the type of KLF1
mutation, making it difficult to clearly separate “quantitative”
from “qualitative” effects of KLF1 mutations.
Indeed, KLF1 coordinately regulates the expression of a
multitude of red cell specific genes including heme biosynthesis
genes [ALAS2, HMBS, TFR2 (Singleton et al., 2008)], red cell
enzymes [such as pyruvate kinase genes -PKLR (Viprakasit et al.,
2014)], globins (see below) or cell cycle proteins (Hodge et al.,
2006; Pilon et al., 2008; Tallack et al., 2009; Gnanapragasam
et al., 2016). Thus, depending on the type of mutation, a specific
subset of targets can be affected, leading to a broad spectrum of
phenotypes (Perkins et al., 2016).
The Semi-Dominant Phenotype in Nan
(Neonatal Anemia) Mouse and in Human
CDAIV
This is particularly evident in the case of the neonatal anemia
(Nan) semi-dominant (Nan/+) mouse phenotype (Heruth et al.,
2010; Siatecka et al., 2010) and in the phenotype observed in
human Congenital dyserythropoietic anemia type IV (CDA IV)
(Wickramasinghe et al., 1991; Arnaud et al., 2010; Jaffray et al.,
2013; Ravindranath et al., 2018). In the Nan mouse model, the
E339D substitution in the second ZnF within the Nan allele,
alters Nan-KLF1 binding specificity, resulting in an aberrant
transcriptome (Gillinder et al., 2017). The homologous E325K
heterozygous mutation in CDA IV patients causes the reduced
expression of a subset of KLF1 targets (such as AQP1 and CD44),
whereas other targets are normally expressed (such as BCAM)
(Singleton et al., 2011). In analogy with the Nan mouse mutation,
it is likely that also in man the E325K mutation could alter the
mutant-KLF1 DNA-binding specificity, resulting in detrimental
gain of function effects. On the basis of the different charge
of the variant residues (Aspartic Acid or Lysine) it is possible
to speculate that subsets of targets can be differentially affected
by the different mutant proteins, likely explaining the distinct
human and mice pathologies (Arnaud et al., 2010; Siatecka et al.,
2010). On the other hand, traits common to mouse and human
phenotypes could likely result from the reduced (50%) WT-KLF1.
The Intricate Link Between KLF1, Globin
Expression and the Hemoglobin
Switching: Direct and Indirect Effects
KLF1 was originally identified by its ability to bind to the
β-globin promoter (Miller and Bieker, 1993) and the connection
between KLF1 and β-thalassemia is demonstrated by the
paradigmatic−87 mutation in the β-globin promoter CACC box
(Feng et al., 1994).
Accordingly, the more evident phenotype of KLF1 knockout
mice is a marked β-thalassemia associated with increased
HBG1/HBG2, suggesting that KLF1 interferes at different levels
with globin genes expression. Indeed, the ablation of KLF1
perturbs the 3-dimensional conformation of the β-globin locus
(Noordermeer and de Laat, 2008; Schoenfelder et al., 2010).
Moreover, mutations creating de novo KLF1 motifs can also
alter the relative expression within the β-locus: this is the
case of the −198 mutation in the γ-promoter that introduces
a new KLF1 binding site, generating the British type HFPH
(Wienert et al., 2017). Besides these direct effects of loss or
gain of KLF1 binding, an intricate network of indirect effects
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downstream to KLF1 haploinsufficiency/mutations must be
considered. Borg et al. (2010) reported a Maltese family with
HPFH and mild hypochromatic microcytic RBCs, caused by the
KLF1 K288X non-sense mutation, ablating the DNA binding
domain. Transcription profiling and functional studies in cells
from these subjects revealed low levels of BCL11a, the most
important known HBG1/HBG2 repressor, suggesting that failure
to properly activate BCL11a is the major cause of the observed
HPFH (Borg et al., 2011). This was proven true also in the KLF1-
deficient mouse model (Zhou et al., 2010). However, the situation
is far more complicated: in another family described shortly
thereafter, KLF1 haploinsufficiency did not result in HPFH (Satta
et al., 2011). Instead, in this family, HPFH was observed only in
compound heterozygotes (non-sense S270X and K332Q missense
mutations) together with increased red cell protoporphyrin,
a trait observed in the Nan mouse phenotype. Large-scale
screening of patients with hemoglobinopathies of different ethnic
origin supported the association of KLF1 mutations with elevated
HbF, thus confirming that KLF1 variants are an important source
of HbF variation (Gallienne et al., 2012). Finally, more subtle
effects of KLF1 polymorphisms also account for an appreciable
proportion of cases with borderline elevated HbA2 (Perseu et al.,
2011). Thus, again, the pleiotropic effects of KLF1 are the sum of
quantitative and qualitative effects, possibly in combination with
other genetic modifiers.
CONCLUSION AND PERSPECTIVES
The recent identification of mutations/variants alleles associated
with RBC traits involving TFs has greatly increased thanks
to new technologies and is expected to further increase in
the next few years. This will help not only to explain so far
unexplained diseases -and possibly to envisage new therapeutic
strategies-, but also to better understand the structure and
function of TFs themselves and their involvement in the different
gene regulatory networks. This, in turn, will shed light on the
contribution of TFs and their target sequences as a source of
genetic variability underlying the wide spectrum of the observed
erythroid phenotypes.
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